Table 1.
Association of sitagliptin and 12-month biomarkers adjusted for baseline biomarker and other covariates.
| 12-month log base-2 transformed biomarker | N | Least squares means for placebo | Least squares means for sitagliptin | Difference in least squares means | F | p value |
|---|---|---|---|---|---|---|
| sDPP4 | 592 | 9.15 (9.11, 9.18) | 9.13 (9.09, 9.17) | −0.02 (−0.07, 0.04) | 0.4 | 0.528 |
| DPP4 activity | 591 | 1.83 (1.71, 1.95) | −0.52 (−0.64, −0.40) | −2.35 (−2.51, −2.18) | 775.32 | <0.001 |
| CRP | 592 | 1.33 (1.18, 1.49) | 1.23 (1.07, 1.39) | −0.11 (−0.33, 0.12) | 0.85 | 0.357 |
| IL-6 | 591 | 0.23 (0.13, 0.33) | 0.24 (0.14, 0.34) | 0.01 (−0.13, 0.15) | 0.01 | 0.918 |
| TNFa | 592 | 1.47 (1.43, 1.52) | 1.48 (1.43, 1.52) | 0.00 (−0.06, 0.07) | 0.01 | 0.920 |
| MCP-1 | 592 | 7.49 (7.45, 7.53) | 7.42 (7.38, 7.46) | −0.07 (−0.13, −0.01) | 4.85 | 0.028 |
Statistically significant p values are indicated by bold print. P values are two-sided and derived from multiple linear regression models. No adjustments were made for multiple comparisons.